Benitec BiopharmaFRA:BJ93 34 Market Cap is €398.81 Mil as of Jul. 05, 2026. GuruFocus rates FRA:BJ93 with a GF Score™ of 34/100. Among 1,426 Biotechnology companies, Benitec Biopharma ranks better than 69.5% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Benitec Biopharma's share price for the quarter that ended in Mar. 2026 was €3.06. Benitec Biopharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 34.35 Mil. Therefore, Benitec Biopharma's market cap for the quarter that ended in Mar. 2026 was €105.12 Mil.
Benitec Biopharma's quarterly market cap
increased
from Sep. 2025 (€80.33 Mil) to Dec. 2025 (€104.82 Mil) and
increased
from Dec. 2025 (€104.82 Mil) to Mar. 2026 (€105.12 Mil).
Benitec Biopharma's annual market cap
increased
from Jun. 2023 (€5.46 Mil) to Jun. 2024 (€30.86 Mil) and
increased
from Jun. 2024 (€30.86 Mil) to Jun. 2025 (€80.33 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Benitec Biopharma's Enterprise Value for Today is €237.34 Mil.
Benitec Biopharma (FRA:BJ93) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Benitec Biopharma Market Cap Related Terms
Benitec Biopharma Market Cap Historical Data
* Premium members only.
The historical data trend for Benitec Biopharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BJ93 vs IPSC, FBRX, AUTL: Market Cap Comparison
For the Biotechnology subindustry, Benitec Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Benitec Biopharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Benitec Biopharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Benitec Biopharma's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Benitec Biopharma (FRA:BJ93) has a Market Cap of €398.81 Mil as of Jul. 05, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Benitec Biopharma and its competitors. According to the industry distribution chart, Benitec Biopharma ranks #435 out of 1426 companies in the Biotechnology industry, placing it in the top 30.5%.
Is Benitec Biopharma's Market Cap too high?
Benitec Biopharma's current Market Cap is €398.81 Mil. Based on the distribution chart, Benitec Biopharma ranks #435 out of 1426 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Benitec Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Benitec Biopharma's Market Cap compare to IPSC and FBRX?
According to the Biotechnology industry distribution chart, Benitec Biopharma ranks #435 out of 1426 companies for Market Cap. This puts Benitec Biopharma in the upper half of its industry. The industry median Market Cap is 119.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.23, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Benitec Biopharma and its competitors. For the Biotechnology industry, the median Market Cap is 119.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Benitec Biopharma's current Market Cap is €398.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Benitec Biopharma stock overvalued right now?
Benitec Biopharma (FRA:BJ93) has a current Market Cap of €398.81 Mil. The current Market Cap is €398.81 Mil. Benitec Biopharma's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Benitec Biopharma (FRA:BJ93), the current Market Cap is €398.81 Mil as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
34GF Score
Get the complete analysis for FRA:BJ93
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BJ93 has been successfully added to your 
